ElevateBio

2018: NIH Prospective Grant of an Exclusive Patent License to ElevateBio for CAR T cancer treatment

Posted on by KEI Staff

The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading →

NIH Preparing to License CAR Treatment Patents to Investors Behind Sovaldi and Soliris

Posted on by Claire Cassedy

In a recent Federal Register notice, the National Institutes of Health (NIH) has announced its intent to grant an exclusive patent license on chimeric antigen receptor (CAR) therapies for the treatment of certain cancers to ElevateBio, a company located in… Continue Reading →